1
|
Owen D, Wei L, Pilcher C, Patel S, Konda B, Shah M, Ferguson S, Benner B, Norman R, Carson W, Smith M, Vogt SM, Verschraegen C, He K, Bertino E, Presley C, Shields P, Carbone D, Otterson G. P79.04 A Phase 2 Trial of Nivolumab and Temozolomide in Extensive Stage Small Cell Lung Cancer: Interim Efficacy Analysis. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
2
|
Li M, Li Z, Kalinski P, Verschraegen C, Clinton S, Yang Y, Mortazavi A, Monk P, Folefac E, Yin M, Parikh A, Yang Y. 156P High TLR3 expression predicts improved survival in patients with clear cell renal cell carcinoma. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
3
|
Hrinczenko B, Spigel D, Iannotti N, Safran H, Taylor M, Bennouna J, Goel S, Leach J, Wong D, Kelly K, Verschraegen C, Bajars M, Manitz J, Ruisi M, Gulley J. Long-term avelumab treatment in patients with advanced non-small cell lung cancer (NSCLC): Post hoc analyses from JAVELIN solid tumour. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
4
|
Jiang YZ, Ma D, Suo C, Shi J, Xue M, Stover DG, Verschraegen C, Kaklamani V, Wang P, Shi L, Huang W, Shao ZM. Abstract P3-07-07: Withdrawn. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-07-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Citation Format: Jiang Y-Z, Ma D, Suo C, Shi J, Xue M, Stover DG, Verschraegen C, Kaklamani V, Wang P, Shi L, Huang W, Shao Z-M. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-07-07.
Collapse
Affiliation(s)
- Y-Z Jiang
- Fudan University Shanghai Cancer Center, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Industrial Technology Institute (SITI), Shanghai, China; SARI Center for Stem Cell and Nanomedicine, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China; The Ohio State University Comprehensive Cancer Center, Columbus; University of Texas Health Science Center San Antonio, San Antonio, China
| | - D Ma
- Fudan University Shanghai Cancer Center, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Industrial Technology Institute (SITI), Shanghai, China; SARI Center for Stem Cell and Nanomedicine, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China; The Ohio State University Comprehensive Cancer Center, Columbus; University of Texas Health Science Center San Antonio, San Antonio, China
| | - C Suo
- Fudan University Shanghai Cancer Center, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Industrial Technology Institute (SITI), Shanghai, China; SARI Center for Stem Cell and Nanomedicine, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China; The Ohio State University Comprehensive Cancer Center, Columbus; University of Texas Health Science Center San Antonio, San Antonio, China
| | - J Shi
- Fudan University Shanghai Cancer Center, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Industrial Technology Institute (SITI), Shanghai, China; SARI Center for Stem Cell and Nanomedicine, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China; The Ohio State University Comprehensive Cancer Center, Columbus; University of Texas Health Science Center San Antonio, San Antonio, China
| | - M Xue
- Fudan University Shanghai Cancer Center, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Industrial Technology Institute (SITI), Shanghai, China; SARI Center for Stem Cell and Nanomedicine, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China; The Ohio State University Comprehensive Cancer Center, Columbus; University of Texas Health Science Center San Antonio, San Antonio, China
| | - DG Stover
- Fudan University Shanghai Cancer Center, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Industrial Technology Institute (SITI), Shanghai, China; SARI Center for Stem Cell and Nanomedicine, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China; The Ohio State University Comprehensive Cancer Center, Columbus; University of Texas Health Science Center San Antonio, San Antonio, China
| | - C Verschraegen
- Fudan University Shanghai Cancer Center, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Industrial Technology Institute (SITI), Shanghai, China; SARI Center for Stem Cell and Nanomedicine, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China; The Ohio State University Comprehensive Cancer Center, Columbus; University of Texas Health Science Center San Antonio, San Antonio, China
| | - V Kaklamani
- Fudan University Shanghai Cancer Center, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Industrial Technology Institute (SITI), Shanghai, China; SARI Center for Stem Cell and Nanomedicine, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China; The Ohio State University Comprehensive Cancer Center, Columbus; University of Texas Health Science Center San Antonio, San Antonio, China
| | - P Wang
- Fudan University Shanghai Cancer Center, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Industrial Technology Institute (SITI), Shanghai, China; SARI Center for Stem Cell and Nanomedicine, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China; The Ohio State University Comprehensive Cancer Center, Columbus; University of Texas Health Science Center San Antonio, San Antonio, China
| | - L Shi
- Fudan University Shanghai Cancer Center, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Industrial Technology Institute (SITI), Shanghai, China; SARI Center for Stem Cell and Nanomedicine, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China; The Ohio State University Comprehensive Cancer Center, Columbus; University of Texas Health Science Center San Antonio, San Antonio, China
| | - W Huang
- Fudan University Shanghai Cancer Center, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Industrial Technology Institute (SITI), Shanghai, China; SARI Center for Stem Cell and Nanomedicine, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China; The Ohio State University Comprehensive Cancer Center, Columbus; University of Texas Health Science Center San Antonio, San Antonio, China
| | - Z-M Shao
- Fudan University Shanghai Cancer Center, Shanghai, China; State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China; Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center and Shanghai Industrial Technology Institute (SITI), Shanghai, China; SARI Center for Stem Cell and Nanomedicine, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China; The Ohio State University Comprehensive Cancer Center, Columbus; University of Texas Health Science Center San Antonio, San Antonio, China
| |
Collapse
|
5
|
Blakaj D, Custer A, Zoller W, Wolfe A, Bhatt A, Grams S, Old M, Kang S, Agrawal A, Ozer E, Wobb J, Rupert R, Mitchell D, Verschraegen C, Rocco J, Bonomi M. A Prospective Analysis of Ototoxicity in Modern Radiation Therapy Treatments for Head and Neck Squamous Cell Carcinoma (HNSCC) Patients Receiving Concomitant Chemo-Radiation (CRT) with Weekly or Tri-weekly Cisplatin (Cis). Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
6
|
Owen D, Burkart J, Patel S, Wei L, Tinoco G, Liebner D, He K, Shields P, Bertino E, Presley C, Johns A, Folefac E, Olencki T, Carbone D, Verschraegen C, Otterson G, Kendra K. Immune related adverse events across cancer types: Incidence, risk factors and survival. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy300.088] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
7
|
Rogers S, Shah H, Yin M, Folefac E, Lee R, Verschraegen C. NKTR-214. PEGylated engineered interleukin-2 (IL-2), CD122-biased immunostimulatory cytokine, Cancer immunotherapy. DRUG FUTURE 2018. [DOI: 10.1358/dof.2018.043.05.2781505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
8
|
Tsimberidou A, Verschraegen C, Weise A, Sarantopoulos J, Lopes G, Nemunaitis J, Victor A, Shaw J, Kaleta R, Kurzrock R. Phase I dose escalation study of M2698, a p70S6K/AKT inhibitor, in patients with advanced cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx367.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
9
|
Chawla S, Van Tine B, Pollack S, Ganjoo K, Elias A, Riedel R, Attia S, Choy E, Okuno S, Agulnik M, von Mehren M, Livingston M, Keedy V, Verschraegen C, Philip T, Bohac C, Lu H, Chen M, Maki R. A phase 2 study of CMB305 and atezolizumab in NY-ESO-1+ soft tissue sarcoma: Interim analysis of immunogenicity, tumor control and survival. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx387.007] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
Ades S, Kumar S, Alam M, Goodwin A, Weckstein D, Dugan M, Ashikaga T, Evans M, Verschraegen C, Holmes CE. Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer. J Thromb Haemost 2015; 13:998-1003. [PMID: 25809746 DOI: 10.1111/jth.12910] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2014] [Accepted: 03/11/2015] [Indexed: 12/21/2022]
Abstract
BACKGROUND Patients with metastatic colon cancer (mCRC) are at increased risk of venous thromboembolism (VTE). Limited preclinical data suggest that the oncogene (KRAS) mutational status of the tumor represents a plausible clinical link to systemic hypercoagulability in cancer patients. OBJECTIVES To determine if a tumor genetic characteristic, KRAS mutational status, is associated with an increased risk of VTE in patients with mCRC. PATIENTS/METHODS A retrospective cohort study of patients with mCRC and KRAS test results was conducted at multiple practice sites across New England in the United States. The primary outcome was a VTE event, defined as deep venous thrombosis (DVT) and/or pulmonary embolism (PE), either 6 months before or at any time after the diagnosis of mCRC. KRAS status (mutated vs. wild type) and other relevant predictors of thrombosis were collected. RESULTS Of 172 histologically confirmed patients with mCRC, 40 developed a VTE (23.3%). Sixty-five patients (37.8%) had a mutant KRAS status. The incidence of VTE and DVT among patients with mutated KRAS was 32.3 and 23.1%, respectively. The corresponding incidence among patients with wild-type KRAS was 17.8 and 9.4%. Odd ratios for the association were 2.21 (95% CI, 1.08-4.53) for VTE and 2.62 (95% CI, 1.12-6.12) for DVT, and remained significant despite adjustment for Khorana score and bevacizumab use. CONCLUSION Tumor mutant KRAS status is associated with an increased risk of VTE in patients with mCRC. The tumor genetic profile may represent a novel and important risk factor for thrombosis in patients with cancer.
Collapse
Affiliation(s)
- S Ades
- Department of Medicine, Vermont Cancer Center, University of Vermont, Burlington, VT, USA
| | - S Kumar
- Department of Medicine, Vermont Cancer Center, University of Vermont, Burlington, VT, USA
| | - M Alam
- The James, Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - A Goodwin
- Department of Pathology and Laboratory Medicine, University of Vermont, Burlington, VT, USA
| | - D Weckstein
- New Hampshire Oncology-Hematology PA, Hookset, NH, USA
| | - M Dugan
- New England Cancer Specialists, Scarborough, ME, USA
| | - T Ashikaga
- Department of Math and Statistics, University of Vermont, Burlington, VT, USA
| | - M Evans
- The James, Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - C Verschraegen
- Department of Medicine, Vermont Cancer Center, University of Vermont, Burlington, VT, USA
| | - C E Holmes
- Department of Medicine, Vermont Cancer Center, University of Vermont, Burlington, VT, USA
| |
Collapse
|
11
|
Tsimberidou A, Verschraegen C, Heestand G, Kaleta R, Scheuenpflug J, Huck B, Weise A, Kurzrock R. A first in human, dose escalation trial of MSC2363318A – a dual p70S6K/Akt inhibitor, for patients with advanced malignancies. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv094.1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
McMeekin S, Patel R, Verschraegen C, Celano P, Burke J, Plaxe S, Ghatage P, Giurescu M, Stredder C, Wang Y, Schmelter T. Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer. Br J Cancer 2012; 106:70-6. [PMID: 22108514 PMCID: PMC3251849 DOI: 10.1038/bjc.2011.499] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2011] [Revised: 10/14/2011] [Accepted: 10/18/2011] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND Sagopilone is the first fully synthetic epothilone in clinical development and has demonstrated promising preclinical activity. This phase I/II, prospective, open-label trial investigated the efficacy and safety of sagopilone plus carboplatin in patients with recurrent platinum-sensitive ovarian cancer (OC). METHODS In phase I (dose-escalation stage), patients with OC recurring at least 6 months after platinum-containing chemotherapy received 3-h infusions of sagopilone (initial dose of 12 mg m(-2)) followed by carboplatin every 3 weeks, for 2-6 treatment courses. Patients enrolled in phase II received 3-h infusions of 16 mg m(-2) sagopilone. Efficacy was assessed using modified Response Evaluation Criteria in Solid Tumors (modRECIST) and Gynecologic Cancer InterGroup CA125 criteria. The safety and tolerability of sagopilone were also evaluated. RESULTS In all, 45 patients received sagopilone at 12 mg m(-2) or 16 mg m(-2). There were 29 confirmed tumour responses (21 modRECIST and 8 CA125) across both treatment groups, indicating that the primary objective of the study was reached. The main adverse events (AEs) reported were peripheral neuropathy (75.6%), fatigue (71.1%) and nausea (64.4%). Grade ≥3 AEs occurred in 35 patients (77.8%). No deaths related to the study drug were reported. CONCLUSION Sagopilone in combination with carboplatin was effective and toxicities were manageable in patients with recurrent platinum-sensitive OC.
Collapse
Affiliation(s)
- S McMeekin
- University of Oklahoma Health Sciences Center, Department of Obstetrics and Gynecology, 825 NE 10th Street, Oklahoma City, OK 73104, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Czok S, Jewell A, Shawki S, Boyd L, Smith H, Blank S, Muller C, Verschraegen C, Muggia F. Pegylated liposomal doxorubicin with bevacizumab in the treatment of platinum-resistant ovarian cancer: Toxicity profile results. Gynecol Oncol 2011. [DOI: 10.1016/j.ygyno.2010.12.198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
14
|
Soonthornthum T, Arias-Pulido H, Joste N, Lomo L, Muller C, Rutledge T, Verschraegen C. Epidermal growth factor receptor as a biomarker for cervical cancer. Ann Oncol 2011; 22:2166-78. [PMID: 21325449 DOI: 10.1093/annonc/mdq723] [Citation(s) in RCA: 76] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
This review focuses on the different modes of expression of the epidermal growth factor receptor (EGFR). All methods used to assess EGFR expression are critically analyzed and insights into the use of inhibitors of EGFR for treatment of cervical cancer are discussed. Currently, expression of EGFR as a biomarker for prognosis or for treatment of cervical cancer is not defined for clinical use.
Collapse
Affiliation(s)
- T Soonthornthum
- Department of Internal Medicine, University of New Mexico Cancer Research and Treatment Center, Albuquerque, NM 87131, USA
| | | | | | | | | | | | | |
Collapse
|
15
|
O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, Verschraegen C, Humphrey R, Ibrahim R, de Pril V, Hoos A, Wolchok JD. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21:1712-1717. [PMID: 20147741 DOI: 10.1093/annonc/mdq013] [Citation(s) in RCA: 390] [Impact Index Per Article: 27.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND This phase II study evaluated the safety and activity of ipilimumab, a fully human mAb that blocks cytotoxic T-lymphocyte antigen-4, in patients with advanced melanoma. PATIENTS AND METHODS Patients with previously treated, unresectable stage III/stage IV melanoma received 10 mg/kg ipilimumab every 3 weeks for four cycles (induction) followed by maintenance therapy every 3 months. The primary end point was best overall response rate (BORR) using modified World Health Organization (WHO) criteria. We also carried out an exploratory analysis of proposed immune-related response criteria (irRC). RESULTS BORR was 5.8% with a disease control rate (DCR) of 27% (N = 155). One- and 2-year survival rates (95% confidence interval) were 47.2% (39.5% to 55.1%) and 32.8% (25.4% to 40.5%), respectively, with a median overall survival of 10.2 months (7.6-16.3). Of 43 patients with disease progression by modified WHO criteria, 12 had disease control by irRC (8% of all treated patients), resulting in a total DCR of 35%. Adverse events (AEs) were largely immune related, occurring mainly in the skin and gastrointestinal tract, with 19% grade 3 and 3.2% grade 4. Immune-related AEs were manageable and generally reversible with corticosteroids. CONCLUSION Ipilimumab demonstrated clinical activity with encouraging long-term survival in a previously treated advanced melanoma population.
Collapse
Affiliation(s)
- S J O'Day
- The Angeles Clinic and Research Institute, Santa Monica, CA, USA.
| | - M Maio
- Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena
| | - V Chiarion-Sileni
- Department of Melanoma and Skin Cancer Unit, IOV-IRCCS, Padua, Italy
| | - T F Gajewski
- Department of Pathology; Department of Medicine, University of Chicago, Chicago, IL, USA
| | - H Pehamberger
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - I N Bondarenko
- Dnepropetrovsk State Medical Academy, Dnepropetrovsk, Ukraine
| | - P Queirolo
- Department of Medical Oncology A, National Institute for Cancer Research, Genova, Italy
| | - L Lundgren
- Department of Oncology, Lund University Hospital, Lund, Sweden
| | - S Mikhailov
- Stavropol Regional Clinical Oncology Center, Stavropol
| | - L Roman
- Leningrad Regional Oncology Center, St Petersburg, Russian Federation
| | | | - R Humphrey
- Bristol-Myers Squibb Company, Wallingford, CT, USA
| | - R Ibrahim
- Bristol-Myers Squibb Company, Wallingford, CT, USA
| | - V de Pril
- Bristol-Myers Squibb Company, Braine-l'Alleud, Belgium
| | - A Hoos
- Bristol-Myers Squibb Company, Wallingford, CT, USA
| | - J D Wolchok
- Department of Medicine and Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| |
Collapse
|
16
|
Arias-Pulido H, Joste N, Lomo L, Chaher N, Lee S, Verschraegen C, Meisner A, Martinez C, Prossnitz E, Royce M. GPR30 and HER-2 Expression in Invasive and Metastatic Breast Cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-4158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: GPR30 expression, a new estrogen receptor, has been previously associated with HER-2, tumor size and metastasis in invasive breast cancer (BC) but its role in paired normal (N), invasive (I), and metastatic (M), samples is unknown. We described GPR30 and HER-2 expression in a collection of paired N/I/M samples, derived from the same individual.Materials and Methods: GPR30 and HER-2 expression was assessed by immunohistochemistry (IHC) in tissue microarrays, containing paraffin-embedded cores from 100 patients diagnosed with invasive BC. N and M samples were also available from the same patient. GPR30 expression was evaluated by an H-score (Intensity (0, negative; 1+, weak; 2+, moderate; 3+, strong) x Percentage of stained epithelial cells). HER-2 expression was evaluated per standard criteria. Log rank tests and Wald tests were employed to assess the clinical impact of these molecular targets on patient outcome based on Kaplan-Meier Product estimator and Cox Proportional Hazard Regression.Results: GPR30 was expressed in 50%, 76%, and 72% of N, I and M, respectively, samples. HER-2 (3+) was found in 14% and 18% of I and M samples, respectively. GPR30 expression in I cases correlated with expression in M cases, and HER-2 expression in I but not M cases. GPR30 expression in M cases correlated with expression in HER-2 expression in M cases. HER-2 expression in I cases correlated with expression in M samples (P<0.05 for all comparisons). GPR30 and HER-2 expression were not associated with grade or stage (P>0.05). GPR30 expression in I or M samples was not associated with either overall survival (OS) or BC-specific survival (BCSS)(P>0.5). HER-2 expression was marginally associated with OS in I (P=0.06; Hazard Ratios (HR): 1.91; 95%CI: 0.956, 3.83) but not in M (P=0.23) cases. HER-2 was significantly associated with BCSS in I cases (P=0.03; HR: 2.39; 95%CI: 1.07, 5.32) and marginally in M (P=0.08) cases.Discussion: A previous study suggested that GPR30 expression predicted the development of metastasis. We found high GPR30 expression in both the primary and metastatic sample but the difference was not significant. While GPR30 expression was not associated with OS or BCSS, HER-2 expression was marginally associated with OS and significantly associated with BCSS in invasive cases.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 4158.
Collapse
Affiliation(s)
| | - N. Joste
- 2University of New Mexico Cancer Center, NM,
| | - L. Lomo
- 2University of New Mexico Cancer Center, NM,
| | - N. Chaher
- 3University Centre Pierre et Marie Curie, Algeria
| | - S. Lee
- 4University of New Mexico Cancer Center, NM,
| | | | - A. Meisner
- 4University of New Mexico Cancer Center, NM,
| | - C. Martinez
- 4University of New Mexico Cancer Center, NM,
| | | | - M. Royce
- 1University of New Mexico Cancer Center, NM,
| |
Collapse
|
17
|
Schadendorf D, Wolchok J, Neyns B, Lebbé C, Harmankaya K, Verschraegen C, Chin K, dePril V, Hoos A, Maio M. 9308 Activity of ipilimumab at 10 mg/kg in patients with advanced melanoma is independent of baseline prognostic factors. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71952-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
18
|
Robert F, Verschraegen C, Hurwitz H, Uronis H, Advani R, Chen A, Taverna P, Wollman M, Fox J, Michelson G. A phase I trial of sns-314, a novel and selective pan-aurora kinase inhibitor, in advanced solid tumor patients. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.2536] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2536 Background: Aurora Kinases are a family of serine/threonine kinases (Aurora Kinases (AK) A, B, and C) critical for mitosis. Elevated AKs expression occurs in a high percentage of melanoma, colon, breast, ovarian, gastric, and pancreatic tumors; in a subset of these tumors the AURKA locus (20q13) is amplified. SNS-314 is a selective pan-AK inhibitor with low nanomolar IC50s. Methods: Study design is 3+3 phase 1 dose escalation by modified Fibonacci. Patients (pts) with advanced solid tumors received SNS-314 by 3 hour infusion qweek X 3 (28 day cycle). Primary endpoints: safety, tolerability, and DLT assessment. Secondary endpoints: MTD, pharmacokinetics (PK), pharmacodynamics, and antitumor activity. Pharmacodynamic endpoint was inhibition of Histone H3 phosphorylation (pHH3) evaluated by immunohistochemistry of skin punch biopsies taken pre- and 2 hours post-infusion. Results: Thirty-two pts (16M/16F; median age = 58.5 years) were enrolled into 8 cohorts: dose range 30–1800 mg/m2. Median cycles received =2. SNS-314 was generally well tolerated with Grade 1–2 toxicities ≥ 15% incidence: nausea (31%), fatigue (28%), vomiting, constipation, and pain (16% each), and no Grade 3+ toxicities of ≥ 15% incidence. A DLT of Grade 3 neutropenia preventing administration of all 3 doses was observed at 1440 mg/m2. Plasma PK were dose proportional for exposure with no accumulation of SNS-314 following weekly administration. Clearance was moderate (5.65 L/hr/m2, CV 39.4%); Vss approximated total body water (21.5 L/m2, CV 78.1%); terminal half-life was 10.4 hours (CV 66.8%). Six patients had stable disease as their best response. Inhibition of pHH3 by SNS-314 was observed in skin biopsies of patients treated at doses of 240 mg/m2 and greater. Conclusions: SNS-314 is a novel inhibitor of AKs A, B, and C. The compound has been generally well tolerated; MTD was not established. No objective responses were observed. Pharmacodynamic activity was demonstrated by inhibition of pHH3. [Table: see text]
Collapse
Affiliation(s)
- F. Robert
- University of Alabama-Birmingham, Birmingham, AL; University of New Mexico, Albuquerque, NM; Duke University, Durham, NC; Stanford University, Palo Alto, CA; Sunesis Pharmaceuticals Inc., South San Francisco, CA
| | - C. Verschraegen
- University of Alabama-Birmingham, Birmingham, AL; University of New Mexico, Albuquerque, NM; Duke University, Durham, NC; Stanford University, Palo Alto, CA; Sunesis Pharmaceuticals Inc., South San Francisco, CA
| | - H. Hurwitz
- University of Alabama-Birmingham, Birmingham, AL; University of New Mexico, Albuquerque, NM; Duke University, Durham, NC; Stanford University, Palo Alto, CA; Sunesis Pharmaceuticals Inc., South San Francisco, CA
| | - H. Uronis
- University of Alabama-Birmingham, Birmingham, AL; University of New Mexico, Albuquerque, NM; Duke University, Durham, NC; Stanford University, Palo Alto, CA; Sunesis Pharmaceuticals Inc., South San Francisco, CA
| | - R. Advani
- University of Alabama-Birmingham, Birmingham, AL; University of New Mexico, Albuquerque, NM; Duke University, Durham, NC; Stanford University, Palo Alto, CA; Sunesis Pharmaceuticals Inc., South San Francisco, CA
| | - A. Chen
- University of Alabama-Birmingham, Birmingham, AL; University of New Mexico, Albuquerque, NM; Duke University, Durham, NC; Stanford University, Palo Alto, CA; Sunesis Pharmaceuticals Inc., South San Francisco, CA
| | - P. Taverna
- University of Alabama-Birmingham, Birmingham, AL; University of New Mexico, Albuquerque, NM; Duke University, Durham, NC; Stanford University, Palo Alto, CA; Sunesis Pharmaceuticals Inc., South San Francisco, CA
| | - M. Wollman
- University of Alabama-Birmingham, Birmingham, AL; University of New Mexico, Albuquerque, NM; Duke University, Durham, NC; Stanford University, Palo Alto, CA; Sunesis Pharmaceuticals Inc., South San Francisco, CA
| | - J. Fox
- University of Alabama-Birmingham, Birmingham, AL; University of New Mexico, Albuquerque, NM; Duke University, Durham, NC; Stanford University, Palo Alto, CA; Sunesis Pharmaceuticals Inc., South San Francisco, CA
| | - G. Michelson
- University of Alabama-Birmingham, Birmingham, AL; University of New Mexico, Albuquerque, NM; Duke University, Durham, NC; Stanford University, Palo Alto, CA; Sunesis Pharmaceuticals Inc., South San Francisco, CA
| |
Collapse
|
19
|
Smylie M, Francis S, Neyns B, Maio M, Minor D, Verschraegen C, Chin K, Ibrahim R, Hoos A, Schadendorf D. Effect of ipilimumab at 10 mg/kg on disease control in patients (pts) with M1c-stage melanoma in relation to baseline lactate dehydrogenase (LDH) levels. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9041] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9041 Background: Ipilimumab, a fully human, anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody, enhances antitumor immunity. Ipilimumab is clinically active in advanced melanoma, with a 1-year survival rate of ∼50% in Phase II studies (Wolchok et al. CRI-CVC annual meeting 2008. Oral presentation). Serum LDH level is an independent prognostic factor for malignant melanoma, and is strongly predictive of reduced survival in stage IV disease (Bedikian et al. J Clin Oncol. 2006;24:4738–4745.). This analysis evaluated the association between baseline LDH levels and disease control (stable or reduced measurable tumor burden) in previously treated pts with M1c-stage melanoma (metastasis to vital organs other than the lungs) who received ipilimumab in 2 recently completed Phase II studies (CA184008 and 022). Methods: Ipilimumab at 10 mg/kg was given every 3 weeks (Q3W) × 4; eligible pts could continue to receive ipilimumab Q12W beginning at Week 24. In study 022, pts were randomized to receive ipilimumab induction dosing at 0.3, 3.0, or 10 mg/kg Q3W × 4; study 008 was a single- arm trial of ipilimumab at 10 mg/kg. Disease control data were pooled from the 2 Phase II studies for pts treated with ipilimumab at 10 mg/kg and stratified by normal and elevated (>1× upper normal limit [UNL]) LDH levels. Elevated LDH was not capped. Results: For 227 pts treated at 10 mg/kg, 123 had M1c-stage disease: 42 had normal LDH and 81 had LDH >1 × UNL (of which 32 had LDH 2 × UNL). Among these 123 pts, 17/81 (21.0%) [95% CI 12.7–31.5] with elevated LDH levels experienced disease control, whereas 12/42 (28.6%) [95% CI 15.7–44.6] with LDH levels at or below the UNL experienced disease control. Conclusions: Our data show that ipilimumab exerts similar disease control in pts with normal and elevated LDH levels. Ipilimumab therefore appears to have clinical activity in the form of disease control in pts with a very poor prognosis, i.e., M1c-stage melanoma and elevated LDH levels. [Table: see text]
Collapse
Affiliation(s)
- M. Smylie
- Cross Cancer Institute, Edmonton, AB, Canada; Bristol-Myers Squibb, Braine l'Alleud, Belgium; Universitair Ziekenhuis, Brussels, Belgium; University Hospital of Siena, Istit Toscano Tumori, Siena, Italy; California Pacific Medical Center, San Francisco, CA; University of New Mexico, Albuquerque, NM; Bristol-Myers Squibb, Wallingford, CT; Universitätsklinikum Mannheim, Mannheim, Germany
| | - S. Francis
- Cross Cancer Institute, Edmonton, AB, Canada; Bristol-Myers Squibb, Braine l'Alleud, Belgium; Universitair Ziekenhuis, Brussels, Belgium; University Hospital of Siena, Istit Toscano Tumori, Siena, Italy; California Pacific Medical Center, San Francisco, CA; University of New Mexico, Albuquerque, NM; Bristol-Myers Squibb, Wallingford, CT; Universitätsklinikum Mannheim, Mannheim, Germany
| | - B. Neyns
- Cross Cancer Institute, Edmonton, AB, Canada; Bristol-Myers Squibb, Braine l'Alleud, Belgium; Universitair Ziekenhuis, Brussels, Belgium; University Hospital of Siena, Istit Toscano Tumori, Siena, Italy; California Pacific Medical Center, San Francisco, CA; University of New Mexico, Albuquerque, NM; Bristol-Myers Squibb, Wallingford, CT; Universitätsklinikum Mannheim, Mannheim, Germany
| | - M. Maio
- Cross Cancer Institute, Edmonton, AB, Canada; Bristol-Myers Squibb, Braine l'Alleud, Belgium; Universitair Ziekenhuis, Brussels, Belgium; University Hospital of Siena, Istit Toscano Tumori, Siena, Italy; California Pacific Medical Center, San Francisco, CA; University of New Mexico, Albuquerque, NM; Bristol-Myers Squibb, Wallingford, CT; Universitätsklinikum Mannheim, Mannheim, Germany
| | - D. Minor
- Cross Cancer Institute, Edmonton, AB, Canada; Bristol-Myers Squibb, Braine l'Alleud, Belgium; Universitair Ziekenhuis, Brussels, Belgium; University Hospital of Siena, Istit Toscano Tumori, Siena, Italy; California Pacific Medical Center, San Francisco, CA; University of New Mexico, Albuquerque, NM; Bristol-Myers Squibb, Wallingford, CT; Universitätsklinikum Mannheim, Mannheim, Germany
| | - C. Verschraegen
- Cross Cancer Institute, Edmonton, AB, Canada; Bristol-Myers Squibb, Braine l'Alleud, Belgium; Universitair Ziekenhuis, Brussels, Belgium; University Hospital of Siena, Istit Toscano Tumori, Siena, Italy; California Pacific Medical Center, San Francisco, CA; University of New Mexico, Albuquerque, NM; Bristol-Myers Squibb, Wallingford, CT; Universitätsklinikum Mannheim, Mannheim, Germany
| | - K. Chin
- Cross Cancer Institute, Edmonton, AB, Canada; Bristol-Myers Squibb, Braine l'Alleud, Belgium; Universitair Ziekenhuis, Brussels, Belgium; University Hospital of Siena, Istit Toscano Tumori, Siena, Italy; California Pacific Medical Center, San Francisco, CA; University of New Mexico, Albuquerque, NM; Bristol-Myers Squibb, Wallingford, CT; Universitätsklinikum Mannheim, Mannheim, Germany
| | - R. Ibrahim
- Cross Cancer Institute, Edmonton, AB, Canada; Bristol-Myers Squibb, Braine l'Alleud, Belgium; Universitair Ziekenhuis, Brussels, Belgium; University Hospital of Siena, Istit Toscano Tumori, Siena, Italy; California Pacific Medical Center, San Francisco, CA; University of New Mexico, Albuquerque, NM; Bristol-Myers Squibb, Wallingford, CT; Universitätsklinikum Mannheim, Mannheim, Germany
| | - A. Hoos
- Cross Cancer Institute, Edmonton, AB, Canada; Bristol-Myers Squibb, Braine l'Alleud, Belgium; Universitair Ziekenhuis, Brussels, Belgium; University Hospital of Siena, Istit Toscano Tumori, Siena, Italy; California Pacific Medical Center, San Francisco, CA; University of New Mexico, Albuquerque, NM; Bristol-Myers Squibb, Wallingford, CT; Universitätsklinikum Mannheim, Mannheim, Germany
| | - D. Schadendorf
- Cross Cancer Institute, Edmonton, AB, Canada; Bristol-Myers Squibb, Braine l'Alleud, Belgium; Universitair Ziekenhuis, Brussels, Belgium; University Hospital of Siena, Istit Toscano Tumori, Siena, Italy; California Pacific Medical Center, San Francisco, CA; University of New Mexico, Albuquerque, NM; Bristol-Myers Squibb, Wallingford, CT; Universitätsklinikum Mannheim, Mannheim, Germany
| |
Collapse
|
20
|
Muggia FM, Boyd L, Liebes L, Downey A, Muller C, Pothuri B, Blank S, Rutledge T, Fishman D, Verschraegen C. Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5548] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5548 Background: PLD activity in platinum-resistant OC is modest. B, with its activity in platinum(Plat)-sensitive and Plat-resistant patients (pts), has not been combined with PLD. PLD intratumoral concentrations, if affected by B, might be reflected in PLD PK. This phase II study of PLD + B was started in 2007 to accrue 48 pts, unless 4 serious (> grade 3) adverse events (AEs) supervened. Methods: Improvement in progression-free survival (PFS) at 6 m from 25 to 40% at 6 m in Plat-resistant OC is primary endpoint. PK of PLD alone at 1h, d 7 and d 21 (cycle 1) vs with B (cycle 2), safety, and response rates (RECIST and CA125 criteria) were secondary endpoints. Dosing: PLD 30 mg/m2 followed by B 15 mg/kg on cycles 2–7 (with option to continue) d 1 every 3 w. Pts recurring within 6 m of platinum-based treatment for OC after < 3 prior regimens (but no PLD or B) were eligible. Exclusions: bowel obstruction, prior perforation, uncontrolled hypertension, or vascular disease. Hematologic, mucocutaneous and renal toxicities were evaluated prior to each cycle, MUGA scans every third cycle; disease status by CA125 and/or RECIST every third cycle. Results: 21 of 24 pts enrolled to date are evaluable. Median age is 65, range 52–83; most had 2 prior chemotherapy regimens. Median 6 (range 3–12) cycles were given with 6 off study with progression at 3–7 cycles. RECIST and CA125 responses are under review; in 11 pts with baseline CA125 of > 40 IU/mL, median increase was 31% by cycle 2; later falling to -57%. AEs did not exceed grade 3; hand-foot syndrome led to PLD dose reduction in 8 pts (33%); asymptomatic decreases in left ventricular ejection fraction (LVEF) >10% in 3 pts were noted, with treatment discontinuation in 1. The mean (±SEM) secondary PK parameter estimates for Cmax, AUC, and elimination half life were 4.5 ± 0.5 ug/mL, 651.7 ± 61 ug/mL x h, and 93.3 ± 19.7 h, respectively. Conclusions: Cycles 1 and 2 PLD PK do not differ. PLD + B is tolerable with PLD dose modifications. Declines in LVEF in 1 institution have uncertain causality. Midway into the trial, safety and time on study encourage completion for study primary endpoint. [Table: see text]
Collapse
Affiliation(s)
- F. M. Muggia
- NYU School of Medicine, New York, NY; University of New Mexico, Albuquerque, NM; University of New Mexico, Albuquerque, NH
| | - L. Boyd
- NYU School of Medicine, New York, NY; University of New Mexico, Albuquerque, NM; University of New Mexico, Albuquerque, NH
| | - L. Liebes
- NYU School of Medicine, New York, NY; University of New Mexico, Albuquerque, NM; University of New Mexico, Albuquerque, NH
| | - A. Downey
- NYU School of Medicine, New York, NY; University of New Mexico, Albuquerque, NM; University of New Mexico, Albuquerque, NH
| | - C. Muller
- NYU School of Medicine, New York, NY; University of New Mexico, Albuquerque, NM; University of New Mexico, Albuquerque, NH
| | - B. Pothuri
- NYU School of Medicine, New York, NY; University of New Mexico, Albuquerque, NM; University of New Mexico, Albuquerque, NH
| | - S. Blank
- NYU School of Medicine, New York, NY; University of New Mexico, Albuquerque, NM; University of New Mexico, Albuquerque, NH
| | - T. Rutledge
- NYU School of Medicine, New York, NY; University of New Mexico, Albuquerque, NM; University of New Mexico, Albuquerque, NH
| | - D. Fishman
- NYU School of Medicine, New York, NY; University of New Mexico, Albuquerque, NM; University of New Mexico, Albuquerque, NH
| | - C. Verschraegen
- NYU School of Medicine, New York, NY; University of New Mexico, Albuquerque, NM; University of New Mexico, Albuquerque, NH
| |
Collapse
|
21
|
Sayar H, Shen Z, Lee SJ, Royce M, Rabinowitz I, Lee F, Smith H, Eberhardt S, Maestas A, Lu H, Verschraegen C. Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies. Invest New Drugs 2008; 27:153-8. [PMID: 18773144 DOI: 10.1007/s10637-008-9172-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2008] [Accepted: 08/18/2008] [Indexed: 01/29/2023]
Abstract
PURPOSE This phase I trial assessed the safety and the maximum tolerated dose of capecitabine given for 10 days prior to a combination of cisplatin and irinotecan in patients with advanced solid malignancies. It also evaluated the changes in cisplatin DNA adducts induced by capecitabine. PATIENTS AND METHODS Patients with refractory solid tumors who had not failed 5-fluorouracil (5-FU) analogs or topoisomerase I inhibitors were eligible. All cohorts of patients first received a 28-day cycle of cisplatin and irinotecan. Both drugs were given at a dose of 50 mg/m(2) intravenously on day 1, followed by irinotecan on days 8 and 15 at the same dose. The first cycle served as an internal control. Starting from the second cycle, patients received increasing doses per cohort of capecitabine from day 1 to 10 of each cycle, followed by cisplatin on day 11 and irinotecan on days 11, 18 and 25, both at same doses as the first cycle. Cycles were repeated every 38 days. The starting dose of capecitabine was 500 mg/m(2)/day which was escalated by 250 mg/m(2)/day in the subsequent cohort of patients to reach the maximum tolerated dose (MTD). Later, additional patients were treated at the MTD of capecitabine to further evaluate the safety, pharmacodynamics, and tumor response. Patients blood was tested for cisplatin-DNA adducts to determine the impact of capecitabine on cisplatin-based therapy. RESULTS Fifteen patients received at least 2 cycles of treatment. At 1,250 mg/m(2), two DLT of prolonged neutropenia of grade > or =3 were observed. The MTD for capecitabine was thus determined to be 1000 mg/m(2)/day. Fatigue and diarrhea of grade 1 or 2 were the most frequent toxicities at this dose level. No significant hematologic toxicity was observed at the MTD. Two complete and three partial remissions were observed. Four of the responders had received a platinum agent and/or 5-FU in the past. CONCLUSIONS A sequential treatment with capecitabine followed by cisplatin and irinotecan is well tolerated and demonstrates clinical activity in patients with advanced solid malignancies. The influence of capecitabine, if any, on the efficacy of the cisplatin-irinotecan combination is not related to a variation in cisplatin-DNA adducts.
Collapse
Affiliation(s)
- H Sayar
- The University of Indiana Cancer Center, Indianapolis, IN, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Verschraegen C, Sweeney C, Chiorean G, Lee F, Jones S, Tye L, Bello A, Chao R, Burris H. 714 POSTER Phase I tolerability/safety of sunitinib in combination with capecitabine in patients (pts) with advanced solid tumors. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70513-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
23
|
Sweeney C, Verschraegen C, Chiorean G, Lee F, Jones S, Tye L, Bello A, Chao R, Burris H. A phase I dose escalation study of sunitinib plus capecitabine in patients with advanced solid tumors. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.3592] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3592 Background: Sunitinib malate (SU) is an oral, multitargeted tyrosine kinase inhibitor of VEGFRs, PDGFRs, KIT, RET, and FLT3, approved internationally for the treatment of advanced RCC and imatinib-resistant or -intolerant GIST. This phase I study assesses the safety, tolerability and pharmacokinetics (PK) of SU in combination with capecitabine (C). Methods: Pts with advanced solid tumors not amenable to curative therapy, previously treated with =2 prior chemotherapy regimens, and ECOG PS =1 were eligible. Prior antiangiogenic therapy was not permitted. Three SU schedules were evaluated: 4 wks on treatment followed by 2 wks off in 6-wk cycles (4/2 schedule); 2 wks on followed by 1 wk off in 3-wk cycles (2/1 schedule), and continuous dosing (CD schedule). In all cases C was administered orally bid on days 1–14. SU and C doses were alternately escalated in serial pt cohorts to determine the maximum tolerated dose (MTD) of SU for all schedules using a standard 3 + 3 design. PK and antitumor efficacy were also assessed. Results: A total of 50 pts have been enrolled; 28 pts have been treated on the 4/2 schedule: SU 50 mg + C 1,000 mg/m2, and SU 37.5 mg + C 1,250 mg/m2 were not tolerated. Dose limiting toxicities (DLTs) included: grade 3 myalgia (n=1), grade 3 fatigue (n=2), and grade 3 hand- foot syndrome (n=2). The MTD for the 4/2 schedule was SU 37.5 mg/day + C 1,000 mg/m2. No DLTs nor dose reductions were observed among 9 pts treated at the MTD. Preliminary PK data do not indicate drug-drug interactions between SU and C. 3 pts (1 each with breast cancer, neuroendocrine carcinoma, and thyroid carcinoma) achieved confirmed partial responses. On the 2/1 schedule patients are being accrued to SU 37.5 or 50 mg + C 1,000 mg/m2 and doses of SU 37.5 mg + C 1,000 mg/m2 or SU 25 mg + C 1,250 mg/m2 are being explored on the CD schedule. Conclusions: The combination of SU 37.5 mg/day (4/2 schedule) with C 1,000 mg/m2 in pts with advanced solid tumors appears tolerable. SU may be administered in combination with C with no apparent drug-drug interaction. Subsequent cohorts will define the MTD of SU administered on the 2/1 and CD schedules. Further studies of this combination in breast cancer are warranted. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. Sweeney
- Indiana University, Indianapolis, IN; University of New Mexico, Albuquerque, NM; Sarah Cannon Research Institute, Nashville, TN; Pfizer Global Research and Development, La Jolla, CA; Pfizer Inc., New York, NY
| | - C. Verschraegen
- Indiana University, Indianapolis, IN; University of New Mexico, Albuquerque, NM; Sarah Cannon Research Institute, Nashville, TN; Pfizer Global Research and Development, La Jolla, CA; Pfizer Inc., New York, NY
| | - G. Chiorean
- Indiana University, Indianapolis, IN; University of New Mexico, Albuquerque, NM; Sarah Cannon Research Institute, Nashville, TN; Pfizer Global Research and Development, La Jolla, CA; Pfizer Inc., New York, NY
| | - F. Lee
- Indiana University, Indianapolis, IN; University of New Mexico, Albuquerque, NM; Sarah Cannon Research Institute, Nashville, TN; Pfizer Global Research and Development, La Jolla, CA; Pfizer Inc., New York, NY
| | - S. Jones
- Indiana University, Indianapolis, IN; University of New Mexico, Albuquerque, NM; Sarah Cannon Research Institute, Nashville, TN; Pfizer Global Research and Development, La Jolla, CA; Pfizer Inc., New York, NY
| | - L. Tye
- Indiana University, Indianapolis, IN; University of New Mexico, Albuquerque, NM; Sarah Cannon Research Institute, Nashville, TN; Pfizer Global Research and Development, La Jolla, CA; Pfizer Inc., New York, NY
| | - A. Bello
- Indiana University, Indianapolis, IN; University of New Mexico, Albuquerque, NM; Sarah Cannon Research Institute, Nashville, TN; Pfizer Global Research and Development, La Jolla, CA; Pfizer Inc., New York, NY
| | - R. Chao
- Indiana University, Indianapolis, IN; University of New Mexico, Albuquerque, NM; Sarah Cannon Research Institute, Nashville, TN; Pfizer Global Research and Development, La Jolla, CA; Pfizer Inc., New York, NY
| | - H. Burris
- Indiana University, Indianapolis, IN; University of New Mexico, Albuquerque, NM; Sarah Cannon Research Institute, Nashville, TN; Pfizer Global Research and Development, La Jolla, CA; Pfizer Inc., New York, NY
| |
Collapse
|
24
|
Nguyen D, Verschraegen C. 74 Rates of thromboembolic events (TEE) in patients with mesothelioma. Lung Cancer 2006. [DOI: 10.1016/s0169-5002(07)70150-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
25
|
Hassan R, Alexander R, Antman K, Boffetta P, Churg A, Coit D, Hausner P, Kennedy R, Kindler H, Metintas M, Mutti L, Onda M, Pass H, Premkumar A, Roggli V, Sterman D, Sugarbaker P, Taub R, Verschraegen C. Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference. Ann Oncol 2006; 17:1615-9. [PMID: 16600983 DOI: 10.1093/annonc/mdl060] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Peritoneal mesothelioma is a rare cancer of the peritoneum with about 250 new cases diagnosed each year in the United States. It is the second most common site for mesothelioma development and accounts for 10-20% of all mesotheliomas diagnosed in the United States. A meeting sponsored by the NIH Office of Rare Diseases was held in Bethesda, Maryland on September 13 and 14, 2004. The objective of this meeting was to review the epidemiology, biology and current surgical and medical management of peritoneal mesothelioma. In addition, the meeting also discussed clinical and pre-clinical evaluation of novel treatments for mesothelioma as well as ongoing laboratory research to better understand this disease. This report summarizes the proceedings of the meeting as well as directions for future clinical and basic research.
Collapse
Affiliation(s)
- R Hassan
- National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 5116, Bethesda, MD 20892-4264 USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Rasila KK, Burger RA, Smith H, Lee FC, Verschraegen C. Angiogenesis in gynecological oncology-mechanism of tumor progression and therapeutic targets. Int J Gynecol Cancer 2006; 15:710-26. [PMID: 16174217 DOI: 10.1111/j.1525-1438.2005.00132.x] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
The purpose of this article is to review the current literature pertaining to various angiogenic stimulators and angiogenesis inhibitors in gynecological malignancies and the relevance of these markers in the prognosis of these diseases. We also summarize the antiangiogenic drugs currently in development and in clinical use in gynecological oncology. The information was obtained from a computer search of MEDLINE for studies published in the English language regarding angiogenesis and angiogenesis inhibitors in gynecological malignancies between 1970 and December 2003; additional sources were identified through cross-referencing. In ovarian cancer, various different angiogenic activators have been found to correlate with microvessed density (MVD), stage, lymph node and peritoneal metastasis, and survival. In cervical cancer, correlation has been seen between increased angiogenic markers and stage, grade, tumor size, and survival. Studies in endometriat cancer show correlation of angiogenic markers with stage, grade, MVD, and survival. Whereas, in gestational trophoblastic neoplasm (GTD) only few markers have been studied, and some correlated with progression. Information on anti angiogenic drugs currently in ongoing and upcoming trials in gynecological malignancies is also presented. Angiogenesis factors may have a prognostic role to play in patients with gynecological cancers and should continue to be investigated as clinically useful tumor markers. Antiangiogenic-targeted therapies offer an attractive strategy for clinical investigation in gynecologic oncology.
Collapse
Affiliation(s)
- K K Rasila
- University of New Mexico Cancer Research and Treatment Center, Albuquerque, New Mexico 87131, USA
| | | | | | | | | |
Collapse
|
27
|
Rabinowitz MJ, Mangalik A, Lee FC, Cathcart C, Verschraegen C, Rabinowitz I. Phase I/II study of carboplatin, vinorelbine and capecitabine in metastatic breast cance. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.722] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - F.-C. Lee
- University of New Mexico, Albuquerque, NM
| | | | | | | |
Collapse
|
28
|
Amin C, Hemphill B, Sittisomwong T, Malpica A, Hunt W, Verschraegen C. Characteristics of patients with endometrial stromal sarcoma. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.5145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C. Amin
- University of New Mexico, Albuquerque, NM; Chulalongkorn University, Bangkok, Thailand; M. D. Anderson Cancer Center, Houston, TX
| | - B. Hemphill
- University of New Mexico, Albuquerque, NM; Chulalongkorn University, Bangkok, Thailand; M. D. Anderson Cancer Center, Houston, TX
| | - T. Sittisomwong
- University of New Mexico, Albuquerque, NM; Chulalongkorn University, Bangkok, Thailand; M. D. Anderson Cancer Center, Houston, TX
| | - A. Malpica
- University of New Mexico, Albuquerque, NM; Chulalongkorn University, Bangkok, Thailand; M. D. Anderson Cancer Center, Houston, TX
| | - W. Hunt
- University of New Mexico, Albuquerque, NM; Chulalongkorn University, Bangkok, Thailand; M. D. Anderson Cancer Center, Houston, TX
| | - C. Verschraegen
- University of New Mexico, Albuquerque, NM; Chulalongkorn University, Bangkok, Thailand; M. D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
29
|
Abstract
Approximately 80% of human ovarian and endometrial cancers and 50% of breast cancers express GnRH and its receptor as part of an autocrine regulatory system. After binding of its ligand the tumor GnRH receptor couples to G-protein alphai and activates a variety of intracellular signaling mechanisms. (1) Through activation of a protein tyrosine phosphatase, autophosphorylation of growth factor receptors is reverted leading to an inhibition of mitogenic signaling and reduced cell proliferation. (2) Through activation of nuclear factor kappa B antiapoptotic mechanisms are induced protecting tumor cells from apoptosis induced, for example, by doxorubicin. (3) Through activation of the Jun kinase pathway AP-1 is induced, leading to cell cycle arrest in the G0/G1 phase. It seems reasonable to speculate that this system enables the tumor cell to reduce proliferation and to activate repair mechanisms while being protected simultaneously from apoptosis. Interestingly, GnRH antagonists show the same activity in this system as agonists, indicating that the dichotomy GnRH agonist-GnRH antagonist defined in the pituitary gonadotrope is not valid for the tumor GnRH system. Recently, a second type of GnRH receptor, specific for GnRH-II, has been identified in ovarian and endometrial cancers, which transmits significantly stronger antiproliferative effects than the GnRH-I receptor. GnRH antagonists have agonistic effects on this type II receptor. In animal models of human cancers, GnRH antagonists had stronger antitumor effects than GnRH agonists. Therefore, we performed a phase II clinical trial with the GnRH antagonist, cetrorelix (10 mg/day), in patients with ovarian or mullerian carcinoma refractory to platinum chemotherapy. Of 17 evaluable patients treated with cetrorelix, 3 obtained a partial remission (18%) which lasted for 2 to 6 months. Furthermore, 6 patients experienced disease stabilization (35%) for up to 1 year. In this very refractory patient population (median number of prior chemotherapies = 3) these results are quite remarkable when compared with palliative chemotherapy. In addition, cytotoxic GnRH analogs have been developed, where for example doxorubicin was covalently coupled to GnRH analogs. These compounds have superior antitumor effects in cancers expressing GnRH receptors as compared with native doxorubicin and allow for a targeted cytotoxic chemotherapy of gynecologic and breast cancers.
Collapse
Affiliation(s)
- G Emons
- Department of Obstetrics and Gynecology, Georg-August-Universitaet, Robert-Koch-Strasse 40, D-37075 Goettingen, Germany.
| | | | | | | | | | | |
Collapse
|
30
|
Balat O, Edwards CL, Verschraegen C, Delclos L. The long term results of radiotherapy with or without surgery in management of advanced vulvar cancer: report of 76 patients. EUR J GYNAECOL ONCOL 2001; 21:426-9. [PMID: 11055502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
BACKGROUND The combination of conservative surgery plus radiotherapy for vulvar cancer has been well established as a therapeutic alternative to extensive radical surgery. This study was undertaken to evaluate the long-term results of radiotherapy with or without surgery in the management of advanced vulvar cancer. PATIENTS AND METHODS The cases of 76 patients who had advanced carcinoma of the vulva treated with different modalities at the University of Texas M.D. Anderson Cancer Center were retrospectively reviewed. Three patients had unstaged disease as a result of previous surgery, 19 had stage II, 40 had stage III, and 14 had stage IV disease. Follow-up ranged from 4 to 17 years (median, 11 years). RESULTS Five-year disease-free survivals were 75, 67, 68 and 52% for treatment groups I, II, III, and IV, respectively. Disease was controlled locally in 83, 80, 73 and 56% of patients in groups I through IV, respectively; the overall rate of local control was 79%. There was no significant difference in primary tumor control, 5-year disease-free survival, or overall survival among the different treatment groups (p=0.1300). However, these rates did differ significantly (p<0.006) based on FIGO stage of disease. CONCLUSION In this report, the cure of vulvar cancers with radiotherapy alone (5-year disease-free survival 52% and local control 56%), the radiotherapeutic salvage of patients with surgical failure and/or large tumors, the improved survival with low morbidity by pre- and postoperative radiotherapy were provocative observations suggesting the value of this therapy for advanced vulvar cancer.
Collapse
Affiliation(s)
- O Balat
- University of Gaziantep, Sabinbey Medical Center, Department of Obstetrics and Gynecology, Turkey
| | | | | | | |
Collapse
|
31
|
Koonsaeng S, Verschraegen C, Freedman R, Bossens M, Kudelka A, Kavanagh J, Sittisomwong T, DeClercq E, Snoeck R. Successful treatment of recurrent vulvar intraepithelial neoplasia resistant to interferon and isotretinoin with cidofovir. J Med Virol 2001; 64:195-8. [PMID: 11360253 DOI: 10.1002/jmv.1036] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Vulvar intraepithelial neoplasias are difficult to eradicate completely without extensive surgical intervention. Cidofovir, a deoxycytidine monophosphate analog, may have a therapeutic role in this disease. A 43-year-old woman with a 20-year history of genital warts presented with extensive vulvar intraepithelial neoplasia III, and refused surgical resection. Topical cidofovir 1% in Beeler base completely eradicated the lesion. Successive treatment applications, however, were necessary. Cidofovir is a promising topical antiviral compound for HPV induced vulvar intraepithelial neoplasia.
Collapse
Affiliation(s)
- S Koonsaeng
- Gynecologic Oncology Unit, National Cancer Institute, Bangkok, Thailand
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Templin S, Scott W, Platsoucas CD. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Clin Cancer Res 2000; 6:2268-78. [PMID: 10873077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
To identify strategies that enhance tumor-specific immunity in patients with ovarian carcinoma, 22 patients received four to six doses of i.p. recombinant IFN-gamma (rIFN-gamma), 200 microg/m2 on days 1, 3, 5, 8, 10, and 12, and i.p. recombinant interleukin 2 (rIL-2), either 6.0 x 10(5) IU/m2 (group A) or 1.0 x 10(5) IU/m2 (group B), on days 9, 10, and 11. Two patients in group A also received T-cell lines expanded from peritoneal tumor-infiltrating lymphocytes (TILs) obtained after i.p. rIFN-gamma/rIL-2 administration. Toxicity was manageable and included five nonhematological grade 3 or 4 events in 22 patients (23%). A patient had normalization of CA-125 values and a progression-free interval of 18 months, after receiving i.p. rIFN-gamma/rIL-2 without TILs. Another patient who received i.p. rIFN-gamma/rIL-2 plus TILs had stabilization of ascites and intra-abdominal tumors and >50% reduction in serum CA-125 values over 6 months. A third patient who received i.p. rIFN-gamma/rIL-2 had stabilization of intra-abdominal tumors and ascites accompanied by CA-125 values of 50 to 100 units over 6 months. T-cell lines for adoptive immunotherapy were developed for only 3 of 20 patients who were treated with rIFN-gamma/rIL-2. Large numbers of CD3- CD56+ adherent cells were expanded in rIL-2 in the remaining patients, precluding the development of T-cell lines. i.p. rIFN-gamma, either alone or followed by rIL-2, increased proportions of human leukocyte antigen (HLA) class I+ and class II+ tumor cells and increased HLA class I staining intensity on peritoneal carcinoma cells. i.p. rIFN-gamma plus rIL-2 also enhanced cytotoxic activity against Daudi and K562 cells and against allogeneic ovarian tumor cells. Increased cytotoxic activity was associated with an increase in the proportion of CD56+ cells. IFN-gamma and IL-2 transcripts were expressed more frequently after rIFN-gamma and rIL-2 treatment. In addition, the proportions of CD45RA+ (naive lymphocytes) were increased, and CD8+ DR+ lymphocytes were increased relative to CD8+ CD69+ cells, which were decreased. IL-10 concentrations in peritoneal fluids were increased after treatment with rIFN-gamma and the higher rIL-2 dosing (group A) but not in those treated with rIFN-gamma and the lower rIL-2 dosing (group B). These results demonstrated that patients with ovarian carcinoma can tolerate treatment with rIFN-gamma and rIL-2 and that rIFN-gamma alone or rIFN-gamma combined with rIL-2 enhances the expression of HLA class I and class II antigens on ovarian tumor cells, although immunosuppressive cytokines, such as transforming growth factor-beta and IL-10, may persist. Treatment with rIFN-gamma/rIL-2 i.p. did not facilitate the production of TIL-derived T-cell lines ex vivo.
Collapse
MESH Headings
- Ascitic Fluid/metabolism
- CA-125 Antigen/blood
- CD3 Complex/biosynthesis
- CD4-Positive T-Lymphocytes/immunology
- CD4-Positive T-Lymphocytes/metabolism
- CD56 Antigen/biosynthesis
- CD8-Positive T-Lymphocytes/immunology
- CD8-Positive T-Lymphocytes/metabolism
- Cell Adhesion
- Cell Membrane/metabolism
- Dose-Response Relationship, Drug
- Enzyme-Linked Immunosorbent Assay
- Female
- Genes, MHC Class I
- Genes, MHC Class II
- Humans
- Immunohistochemistry
- Immunotherapy, Adoptive
- Injections, Intraperitoneal
- Interferon-gamma/pharmacology
- Interleukin-10/biosynthesis
- Interleukin-2/pharmacology
- K562 Cells
- Leukocytes, Mononuclear/immunology
- Leukocytes, Mononuclear/metabolism
- Lymphocytes, Tumor-Infiltrating/immunology
- Lymphocytes, Tumor-Infiltrating/metabolism
- Neopterin/biosynthesis
- Ovarian Neoplasms/drug therapy
- Ovarian Neoplasms/immunology
- Peritoneal Neoplasms/drug therapy
- Peritoneal Neoplasms/immunology
- RNA, Messenger/metabolism
- Recombinant Proteins/pharmacology
- Reverse Transcriptase Polymerase Chain Reaction
- Transforming Growth Factor beta/biosynthesis
- Transforming Growth Factor beta2
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- R S Freedman
- Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Rahman Z, Kavanagh J, Champlin R, Giles R, Hanania E, Fu S, Zu Z, Mehra R, Holmes F, Kudelka A, Claxton D, Verschraegen C, Gajewski J, Andreeff M, Heimfeld S, Berenson R, Ellerson D, Calvert L, Mechetner E, Holzmayer T, Dayne A, Hamer J, Bachier C, Ostrove J, Deisseroth A. Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. Clin Cancer Res 1998; 4:2717-21. [PMID: 9829734] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
Most patients relapse after high-dose chemotherapy (HDCT) with autologous stem-cell transplantation (ASCT) for metastatic breast cancer. Further chemotherapy immediately after hematopoietic recovery from ASCT is not given for fear of irreversibly damaging the newly engrafted stem cells. In a pilot chemoprotection trial, autologous CD34+ cells from patients with metastatic breast cancer were exposed to a replication-incompetent retroviral vector carrying MDR-1 cDNA and then reinfused after HDCT. Immediately on recovery, patients received multiple courses of escalating dose paclitaxel. All of the 10 patients tolerated reinfusion of modified cells without any toxicity and had myeloid engraftment within 12 days (range, 11-14). The bone marrow cells of three patients contained vector MDR-1-positive cells only at the time of the first course of posttransplant paclitaxel, indicating that the MDR-1 vector-modified cells had only short-term engrafting potential. A total of 83 courses of paclitaxel were administered starting at a median of 30 (range, 21-32) days from ASCT. The median dose of paclitaxel was 225 mg/m2 and the median interval between paclitaxel cycles of therapy was 21 (range, 20-41) days. Five of the six CR patients were able to receive all of the 12 courses of paclitaxel. Three patients who had achieved less than a complete response to the HDCT (2 patients) and partial response (1 patient) were converted to complete clinical responses during the 12 cycles of paclitaxel. No delayed toxicity or bone marrow failure was noted in these patients with a median follow-up of 2 years from ASCT. This is the first study of chemotherapy immediately after transplantation with autologous CD34+ cells. These data indicate that paclitaxel can be safely administered immediately after ASCT without any delayed toxicities. Paclitaxel given immediately after ASCT can further improve the response to pretransplant chemotherapy in patients with advanced breast cancer.
Collapse
Affiliation(s)
- Z Rahman
- The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Melichar B, Savary C, Kudelka AP, Verschraegen C, Kavanagh JJ, Edwards CL, Platsoucas CD, Freedman RS. Lineage-negative human leukocyte antigen-DR+ cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis. Clin Cancer Res 1998; 4:799-809. [PMID: 9533550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The characteristics of antigen-presenting cells in carcinomas that involve the abdominopelvic cavity are unknown. Dendritic cells, a population of antigen-presenting cells, have been identified as lineage-negative human leukocyte antigen (HLA)-DR+ cells by two-color flow cytometry. We used this criterion to study the putative dendritic cells in ascites from 25 patients with peritoneal carcinomatosis. The mean proportion +/- SD of lineage-negative HLA-DR+ cells in ascites was 3.1 +/- 4.6% (range, 0.05-17.3%). Most lineage-negative HLA-DR+ cells expressed CD45RA or CD4 antigens. Dendritic cells had low proportions of CD80, CD11c, CD45RO, and CD58, suggesting that they were of low maturity. The proportion of lineage-negative HLA-DR+ cells in ascites of seven patients was significantly higher than the proportion in peripheral blood from the identical patients (4.5 +/- 5.7 versus 0.5 +/- 0.4; P < 0.05). In paired specimens of ascites and peripheral blood, the proportion of lineage-negative HLA-DR+ cells that coexpressed CD86 or CD58 was significantly lower in ascites than in peripheral blood, whereas a higher proportion of lineage-negative HLA-DR+ cells in ascites expressed CD4. Relative fluorescence intensity of HLA-DR+ was also lower in dendritic cells from ascites and blood from patients with carcinomatosis than it was in blood from normal donors. As an indicator of macrophage activation, the concentration of neopterin in ascitic fluid correlated negatively with the numbers of lineage-negative HLA-DR+ cells in ascites (Spearman correlation coefficient, -0.44; P = 0.05) correlated positively with the concentration of interleukin 10 in ascitic fluid (Spearman correlation coefficient, -0.40; P = 0.05). IFN-gamma and tumor necrosis factor alpha were also not detected. These findings suggest that certain factors associated with the tumor microenvironment might influence the number of these dendritic cells and their expression of function-associated markers.
Collapse
Affiliation(s)
- B Melichar
- Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
| | | | | | | | | | | | | | | |
Collapse
|
35
|
van Besien K, Verschraegen C, Mehra R, Giralt S, Kudelka AP, Edwards CL, Piamsonboom S, Termrungruanglert W, Champlin R, Kavanagh JJ. Complete remission of refractory gestational trophoblastic disease with brain metastases treated with multicycle ifosfamide, carboplatin, and etoposide (ICE) and stem cell rescue. Gynecol Oncol 1997; 65:366-9. [PMID: 9159354 DOI: 10.1006/gyno.1997.4677] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Patients with chemotherapy-refractory gestational trophoblastic disease and brain metastasis are considered to have a very poor prognosis. We present the case of a patient who had failed several chemotherapeutic regimens. Despite transient responses to chemotherapy, she had not achieved a complete remission in 3 years, and had developed systemic disease and recurrent brain metastasis. She was treated with four cycles of high-dose ifosfamide, carboplatin, and etoposide with blood progenitor cell support. She tolerated this regimen well and has obtained a complete remission that is ongoing for 12 months.
Collapse
Affiliation(s)
- K van Besien
- Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Balat O, Verschraegen C, Erbilen M, Edwards C, Silva E, Kudelka A, Kavanagh J. Recurrence of ovarian cancer as a delayed solitary parenchymal splenic metastasis. Int J Gynecol Cancer 1996. [DOI: 10.1046/j.1525-1438.1996.06060496.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
37
|
Kudelka AP, Tresukosol D, Edwards CL, Freedman RS, Levenback C, Chantarawiroj P, Gonzalez de Leon C, Kim EE, Madden T, Wallin B, Hord M, Verschraegen C, Raber M, Kavanagh JJ. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996; 14:1552-7. [PMID: 8622071 DOI: 10.1200/jco.1996.14.5.1552] [Citation(s) in RCA: 185] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
PURPOSE To determine the efficacy and toxicity of topotecan administered as a 5-day intravenous infusion in patients with advanced ovarian cancer refractory to cisplatin-based chemotherapy. PATIENTS AND METHODS Thirty patients with advanced epithelial ovarian cancer refractory to cisplatin-based chemotherapy received intravenous infusions of topotecan 1.5 mg/m2 delivered over 30 minutes each day for 5 days. A course was repeated every 21 days. The patient eligibility requirements included age > or = 18 years, Zubrod score < or = 2, measurable disease, adequate hepatic and renal function, neutrophil count > or = 1,500/microL, platelet count > or = 100,000/microL, and anticipated survival > or = 3 months. RESULTS Twenty eight patients were assessable for response and toxicity. All patients were assessable for survival. The major toxicity from administration of topotecan at this dose schedule was myelosuppression; 21 patients required dose reductions. Four patients had neutropenic fever that required hospitalization, and seven patients required platelet transfusions. Maculopapular pruritic exanthema occurred in 20% of patients; gastrointestinal side effects were mild. No deaths were reported on the study. At dose levels of 1.5, 1.25, and 1.0 mg/m2, 61%, 31%, and 25% of patients, respectively, required dose reductions. Of 28 assessable patients, four (14%; 95% confidence interval [CI], 4% to 34%) achieved a partial response (PR) at a median of 1.4 months and lasting 8.9 months, and 17 had stable disease (SD). The overall median survival time was 10.0 months (95% CI, 8.1 to 13.5). CONCLUSION Topotecan shows modest clinical activity against cisplatin-refractory ovarian cancer, although the dose-intensity is compromised by the depth of the granulocyte nadir and the duration of granulocytopenia. Further studies of topotecan may necessitate a reevaluation of optimal dose schedule, with the possible incorporation of multilineage cytokines, and its activity in taxane-resistant tumors.
Collapse
Affiliation(s)
- A P Kudelka
- University of Texas M.D. Anderson Cancer Center, Houston 77030, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Abstract
Acute blindness or seizures are usually the first signs of central neurotoxicity from cisplatin. We report a case of subacute neurotoxicity caused by cisplatin. Progressive encephalopathy and partial loss of vision were the main observed signs. This condition was completely reversible upon cisplatin discontinuation, as is usually the case with acute central neurotoxicity.
Collapse
Affiliation(s)
- C Verschraegen
- M. D. Anderson Cancer Center, University of Texas, Houston 77030, USA
| | | | | |
Collapse
|